ReviewDigestive diseases and sciences2016
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Review in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions.Hepatology communications · 2021Pooled it
- Gut-Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation.International journal of molecular sciences · 2025Review
- Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?Journal of endocrinological investigation · 2023Review
- FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer.Oncoimmunology · 2023Article
- Beneficial Activities ofNutrients · 2022Article
- Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPARγ/PGC-1α/HNF-4α in Hep3B Cells.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Article
- Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis.Scientific reports · 2021Article
- Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function.Biomarker research · 2020Article
- NAFLD in children: new genes, new diagnostic modalities and new drugs.Nature reviews. Gastroenterology & hepatology · 2019Review
- Hypercholesterolemia Due to Lipoprotein X: Case Report and Thematic Review.Clinical medicine insights. Endocrinology and diabetes · 2019Article
- Oxysterols and Gastrointestinal Cancers Around the Clock.Frontiers in endocrinology · 2019Review
- Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.MedChemComm · 2018Article
- New treatments and therapeutic targets for IBS and other functional bowel disorders.Nature reviews. Gastroenterology & hepatology · 2018Review
- Update on FXR Biology: Promising Therapeutic Target?International journal of molecular sciences · 2018Review
- Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.Journal of computer-aided molecular design · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27734248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.